| pubmed-article:17201409 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:17201409 | lifeskim:mentions | umls-concept:C0020792 | lld:lifeskim |
| pubmed-article:17201409 | lifeskim:mentions | umls-concept:C0134835 | lld:lifeskim |
| pubmed-article:17201409 | lifeskim:mentions | umls-concept:C0036079 | lld:lifeskim |
| pubmed-article:17201409 | lifeskim:mentions | umls-concept:C0034423 | lld:lifeskim |
| pubmed-article:17201409 | lifeskim:mentions | umls-concept:C0243076 | lld:lifeskim |
| pubmed-article:17201409 | lifeskim:mentions | umls-concept:C0205210 | lld:lifeskim |
| pubmed-article:17201409 | lifeskim:mentions | umls-concept:C1553030 | lld:lifeskim |
| pubmed-article:17201409 | lifeskim:mentions | umls-concept:C0205549 | lld:lifeskim |
| pubmed-article:17201409 | lifeskim:mentions | umls-concept:C0072878 | lld:lifeskim |
| pubmed-article:17201409 | lifeskim:mentions | umls-concept:C1870441 | lld:lifeskim |
| pubmed-article:17201409 | pubmed:issue | 1 | lld:pubmed |
| pubmed-article:17201409 | pubmed:dateCreated | 2007-1-4 | lld:pubmed |
| pubmed-article:17201409 | pubmed:abstractText | P-selectin-PSGL-1 interaction causes rolling of leukocytes on the endothelial cell surface, which subsequently leads to firm adherence and leukocyte transmigration through the vessel wall into the surrounding tissues. P-selectin is upregulated on the surface of both platelets and endothelium in a variety of atherosclerosis-associated conditions. Consequently, inhibition of this interaction by means of a small molecule P-selectin antagonist is an attractive strategy for the treatment of atherosclerosis. High-throughput screening and subsequent analoging had led to the identification of compound 1 as the lead candidate. Herein, we report the continuation of this work and the discovery of a second-generation series, the tetrahydrobenzoquinoline salicylic acids. These compounds have improved pharmacokinetic properties, and a number of them have shown oral efficacy in mouse and rat models of atherogenesis and vascular injury. The lead 31 (PSI-697), is currently in clinical development for the treatment of atherothrombotic vascular events. | lld:pubmed |
| pubmed-article:17201409 | pubmed:language | eng | lld:pubmed |
| pubmed-article:17201409 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:17201409 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:17201409 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:17201409 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:17201409 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:17201409 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:17201409 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:17201409 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:17201409 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:17201409 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:17201409 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:17201409 | pubmed:month | Jan | lld:pubmed |
| pubmed-article:17201409 | pubmed:issn | 0022-2623 | lld:pubmed |
| pubmed-article:17201409 | pubmed:author | pubmed-author:StentV CVC | lld:pubmed |
| pubmed-article:17201409 | pubmed:author | pubmed-author:WangQinQ | lld:pubmed |
| pubmed-article:17201409 | pubmed:author | pubmed-author:ShawGray DGD | lld:pubmed |
| pubmed-article:17201409 | pubmed:author | pubmed-author:CamphausenRay... | lld:pubmed |
| pubmed-article:17201409 | pubmed:author | pubmed-author:KailaNeeluN | lld:pubmed |
| pubmed-article:17201409 | pubmed:author | pubmed-author:BedardPatrici... | lld:pubmed |
| pubmed-article:17201409 | pubmed:author | pubmed-author:SchaubRobert... | lld:pubmed |
| pubmed-article:17201409 | pubmed:author | pubmed-author:MorettoAlessa... | lld:pubmed |
| pubmed-article:17201409 | pubmed:author | pubmed-author:KeithJames... | lld:pubmed |
| pubmed-article:17201409 | pubmed:author | pubmed-author:ClerinValerie... | lld:pubmed |
| pubmed-article:17201409 | pubmed:author | pubmed-author:TsaoDesirée... | lld:pubmed |
| pubmed-article:17201409 | pubmed:author | pubmed-author:SushkovaNatal... | lld:pubmed |
| pubmed-article:17201409 | pubmed:author | pubmed-author:JanzKristinK | lld:pubmed |
| pubmed-article:17201409 | pubmed:author | pubmed-author:DeBernardoSil... | lld:pubmed |
| pubmed-article:17201409 | pubmed:author | pubmed-author:HuangAdrianA | lld:pubmed |
| pubmed-article:17201409 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:17201409 | pubmed:day | 11 | lld:pubmed |
| pubmed-article:17201409 | pubmed:volume | 50 | lld:pubmed |
| pubmed-article:17201409 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:17201409 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:17201409 | pubmed:pagination | 40-64 | lld:pubmed |
| pubmed-article:17201409 | pubmed:meshHeading | pubmed-meshheading:17201409... | lld:pubmed |
| pubmed-article:17201409 | pubmed:meshHeading | pubmed-meshheading:17201409... | lld:pubmed |
| pubmed-article:17201409 | pubmed:meshHeading | pubmed-meshheading:17201409... | lld:pubmed |
| pubmed-article:17201409 | pubmed:meshHeading | pubmed-meshheading:17201409... | lld:pubmed |
| pubmed-article:17201409 | pubmed:meshHeading | pubmed-meshheading:17201409... | lld:pubmed |
| pubmed-article:17201409 | pubmed:meshHeading | pubmed-meshheading:17201409... | lld:pubmed |
| pubmed-article:17201409 | pubmed:meshHeading | pubmed-meshheading:17201409... | lld:pubmed |
| pubmed-article:17201409 | pubmed:meshHeading | pubmed-meshheading:17201409... | lld:pubmed |
| pubmed-article:17201409 | pubmed:meshHeading | pubmed-meshheading:17201409... | lld:pubmed |
| pubmed-article:17201409 | pubmed:meshHeading | pubmed-meshheading:17201409... | lld:pubmed |
| pubmed-article:17201409 | pubmed:meshHeading | pubmed-meshheading:17201409... | lld:pubmed |
| pubmed-article:17201409 | pubmed:meshHeading | pubmed-meshheading:17201409... | lld:pubmed |
| pubmed-article:17201409 | pubmed:meshHeading | pubmed-meshheading:17201409... | lld:pubmed |
| pubmed-article:17201409 | pubmed:meshHeading | pubmed-meshheading:17201409... | lld:pubmed |
| pubmed-article:17201409 | pubmed:meshHeading | pubmed-meshheading:17201409... | lld:pubmed |
| pubmed-article:17201409 | pubmed:meshHeading | pubmed-meshheading:17201409... | lld:pubmed |
| pubmed-article:17201409 | pubmed:meshHeading | pubmed-meshheading:17201409... | lld:pubmed |
| pubmed-article:17201409 | pubmed:meshHeading | pubmed-meshheading:17201409... | lld:pubmed |
| pubmed-article:17201409 | pubmed:meshHeading | pubmed-meshheading:17201409... | lld:pubmed |
| pubmed-article:17201409 | pubmed:year | 2007 | lld:pubmed |
| pubmed-article:17201409 | pubmed:articleTitle | 2-(4-Chlorobenzyl)-3-hydroxy-7,8,9,10-tetrahydrobenzo[H]quinoline-4-carboxylic acid (PSI-697): identification of a clinical candidate from the quinoline salicylic acid series of P-selectin antagonists. | lld:pubmed |
| pubmed-article:17201409 | pubmed:affiliation | Chemical and Screening Sciences, Cardiovascular and Metabolic Disease, Drug Safety and Metabolism, Wyeth Research, Cambridge, Massachusetts 02140, USA. nkaila@wyeth.com | lld:pubmed |
| pubmed-article:17201409 | pubmed:publicationType | Journal Article | lld:pubmed |
| http://linkedlifedata.com/r... | http://linkedlifedata.com/r... | pubmed-article:17201409 | lld:chembl |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:17201409 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:17201409 | lld:pubmed |
